🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#MDSs are heterogeneous stem cell malignancies characterized by poor prognosis and no curative therapies outside of allogeneic hematopoietic stem cell transplantation. ow.ly/URvQ50VfXra #clinicaltrialsandobservations #myeloidneoplasia

Thrilled to see our effort on behalf of International Consortium for MDS (icMDS) group out in Blood Journal about reducing clinical trial eligibility barriers for our MDS patients. Commentary by Lionel Ades on ‘ releasing the brake’ on eligibility criteria. Amer Zeidan MBBS,MHS ‏عامر زيدان #mdssm ashpublications.org/blood/article/…

In this episode of ASTCT Talks, Corey Cutler is joined by Steven Pavletic M.D., Ph.D., the GVHD and Late Effects Section and Myeloid Malignancies Program Director at NIH. Listen at the link here or wherever you get podcasts: ow.ly/x8oJ50VlXMe

Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL) | Leukemia nature.com/articles/s4137…

6th Annual MDS/MPN US Focus Meeting kicks off! Stellar agenda by co-chairs Rami komrokji & Prithviraj Bose , opening remarks #RyanFitzpatrick MD Education. Let the learning begin! #HemOnc #MDS #MPN #MedEd

Novel investigational therapies in lower-risk MDS - Yazan Madanat, MD Rami komrokji oncodaily.com/url/274245 #MDS #Cancer #OncoDaily #Oncology #GlobalAwareness #FightAgainstCancer

I enjoyed reading/learning about TI-CH paper in ⁦NEJM⁩ =>Tumor-Infiltrating Clonal Hematopoiesis | Work from ⁦⁦Oriol Pich⁩ ⁦Elsa Bernard⁩ Elli Papaemmanuil, PhD, ⁦Charles Swanton⁩ + team! Editorial by ⁦Dana-Farber⁩ Ebert/Weeks nejm.org/doi/full/10.10…

Bidding farewell to a giant, a mentor, and above all, a friend. Congratulations Steven Pavletic M.D., Ph.D. on an incredible career; can’t wait to see what your next chapter holds. NIH National Cancer Institute

US Geriatric Assessment Practices for Older Adults Undergoing Hematopo... sciencedirect.com/science/articl… In a first of its kind team effort with a so grateful for the commitment and mentorship by all! Mehdi Hamadani, MD,Andy Artz, Paul Carpenter ASTCT improving our survey methodologies🤞🏼

Myelodysplastic syndromes/neoplasms are a heterogenous group of clonal stem cell disorders characterized by morphological dysplasia, defective hematopoiesis, and recurrent genetic abnormalities. ow.ly/TA2750VLGNJ #HowITreat #myeloidneoplasia

"Many brilliant people from my country have lost everything to war. They may be just as capable as me, or even more so, but they have not had the same chances," Dr. Elias Jabbour of MD Anderson Cancer Center wrote in this SOHO Insider letter. sohoinsider.com/leukemia/the-f…

When someone I look up to so much sends me a pic like this…

Fantastic talk by Amer Zeidan MBBS,MHS ‏عامر زيدان Yale Cancer Center at #MDS25 MDS Foundation, using '#BoulevardofBrokenDreams' to describe the challenges in higher-risk MDS drug development. #The18thInternationalCongress on #MDS youtu.be/Soa3gO7tL-c?si…

I’m an oncologist. Here are 11 science-based ways to reduce your cancer risk. My latest essay ⁦The Washington Post⁩ (and I practice what I preach!) ⁦Sylvester Comprehensive Cancer Center⁩ ⁦UMiami Health System⁩ ⁦Journal of Clinical Oncology⁩ ⁦ASH⁩ washingtonpost.com/wellness/2025/…

Excited to see our NHLBI work on infections and immunodeficiency in patients with #telomere biology disorders now published in Blood Journals Portfolio. >1/3 had significant infection history and nearly 1/2 t-lymphopenia. Fernando Catto & Fernanda Gutierrez-Rodrigues. ashpublications.org/blood/article-…

I've long been fascinated by the role of iron chelation- and its disordered metabolism- in MDS, particularly in the context of transplantation. This effort led by Fieke Hoff Steven Pavletic M.D., Ph.D. and Ed Schulz emerged from that curiosity. doi.org/10.1016/j.blre…

FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies | FDA fda.gov/vaccines-blood…

Dr. Rami Komrokji is personally inviting YOU to #SOHO2025. Don't let him down. Register today at soho.click/2025. 💯 Rami komrokji

A unique approach to UCB transplantation

Revisiting #aminmaalouf This ageless piece of art seems particularly relevant nowadays.